Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer

TL;DR: Increasing age, UL, co-morbidity and time since RP are associated with decreasing post-RP WA, warranting consideration of patients’ work plans when considering post- RP oncological treatment.

TL;DR: Whether biopsy cores taken via a transrectal approach from the anterior apical region of the prostate in a repeat‐biopsy population can result in an increased overall cancer detection rate and in more accurate assessment of the Gleason score is evaluated.

TL;DR: This work reviews the current state of prognostic and predictive tissue-based molecular biomarkers which can be used to direct localized prostate cancer treatment decisions, specifically those implicated with definitive and salvage radiation therapy.

TL;DR: In this article, the authors describe and compare health-related quality of life (HRQOL) of prostate cancer patients who received either radical prostatectomy (nerve-sparing, nsRP, or non-nerve sparing, nnsRP) or radiotherapy (external RT, brachytherapy, or both combined) for treatment of localised prostate cancer.

TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.

TL;DR: The strategy of initial conservative management and delayed hormone therapy is a reasonable choice for some men with grade 1 or 2 clinically localized prostate cancer, particularly for those who have an average life expectancy of 10 years or less.

TL;DR: There is a high rate of clinical and chemical freedom from progression following 125I implantation for select patients with early stage prostatic carcinoma.